Literature DB >> 24768585

Renin angiotensin system modulates mTOR pathway through AT2R in HIVAN.

Partab Rai1, Rivka Lederman1, Shabirul Haque1, Shabina Rehman1, Viki Kumar1, Kavithalakshmi Sataranatrajan2, Ashwani Malhotra1, Balakuntalam S Kasinath2, Pravin C Singhal3.   

Abstract

Mammalian target of rapamycin (mTOR) has been reported to contribute to the development of HIV-associated nephropathy (HIVAN). We hypothesized that HIV may be activating renal tissue mTOR pathway through renin angiotensin system (RAS) via Angiotensin Receptor Type II receptor (AT2R). Renal tissues of Vpr transgenic and Tg26 (HIVAN) mice displayed enhanced phosphorylation of mTOR and p70S6K. Aliskiren, a renin inhibitor attenuated phosphorylation of both mTOR and p70S6K in renal tissues of HIVAN mice. Interestingly, Angiotensin Receptor Type I (AT1R) blockade did not modulate renal tissue phosphorylation of mTOR in HIVAN mice; on the other hand, AT2R blockade attenuated renal tissue phosphorylation of mTOR in HIVAN mice. In vitro studies, both renin and Ang II displayed enhanced mouse tubular cell (MTC) phosphorylation of p70S6K in a dose dependent manner. HIV/MTC also displayed enhanced phosphorylation of both mTOR and p70S6K; interestingly this effect of HIV was further enhanced by losartan (an AT1R blocker). On the other hand, AT2R blockade attenuated HIV-induced tubular cell phosphorylation of mTOR and p70S6K, whereas, AT2R agonist enhanced phosphorylation of mTOR and p70S6K. These findings indicate that HIV stimulates mTOR pathway in HIVAN through the activation of renin angiotensin system via AT2R.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Angiotensin II type 1 receptor; Angiotensin II type II receptor; Renal proximal tubular cells; Renin

Mesh:

Substances:

Year:  2014        PMID: 24768585      PMCID: PMC4083194          DOI: 10.1016/j.yexmp.2014.04.004

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  38 in total

Review 1.  Angiotensin receptors and their therapeutic implications.

Authors:  K K Griendling; B Lassègue; R W Alexander
Journal:  Annu Rev Pharmacol Toxicol       Date:  1996       Impact factor: 13.820

2.  Expression of angiotensin II AT2 receptor mRNA during development of rat kidney and adrenal gland.

Authors:  S Shanmugam; C Llorens-Cortes; E Clauser; P Corvol; J M Gasc
Journal:  Am J Physiol       Date:  1995-05

Review 3.  Angiotensin II receptors and angiotensin II receptor antagonists.

Authors:  P B Timmermans; P C Wong; A T Chiu; W F Herblin; P Benfield; D J Carini; R J Lee; R R Wexler; J A Saye; R D Smith
Journal:  Pharmacol Rev       Date:  1993-06       Impact factor: 25.468

4.  Angiotensin II type AT(2) receptor mRNA expression and renal vasodilatation are increased in renal failure.

Authors:  R Bautista; A Sánchez; J Hernández; A Oyekan; B Escalante
Journal:  Hypertension       Date:  2001-09       Impact factor: 10.190

5.  Persistent proteinuria up-regulates angiotensin II type 2 receptor and induces apoptosis in proximal tubular cells.

Authors:  Nuria Tejera; Dulcenombre Gómez-Garre; Alberto Lázaro; Julio Gallego-Delgado; Covadonga Alonso; Julia Blanco; Alberto Ortiz; Jesús Egido
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

6.  Glomerular angiotensin II receptor subtypes during development of rat kidney.

Authors:  G M Ciuffo; M Viswanathan; A M Seltzer; K Tsutsumi; J M Saavedra
Journal:  Am J Physiol       Date:  1993-08

7.  Renal expression of angiotensin type 2 (AT2) receptors during kidney damage.

Authors:  Marta Ruiz-Ortega; Vanesa Esteban; Yusuke Suzuki; Mónica Ruperez; Sergio Mezzano; Leopoldo Ardiles; Pilar Justo; Alberto Ortiz; Jesús Egido
Journal:  Kidney Int Suppl       Date:  2003-10       Impact factor: 10.545

Review 8.  Pathogenesis and treatment of HIV-associated renal diseases: lessons from clinical and animal studies, molecular pathologic correlations, and genetic investigations.

Authors:  Paul L Kimmel; Laura Barisoni; Jeffrey B Kopp
Journal:  Ann Intern Med       Date:  2003-08-05       Impact factor: 25.391

9.  Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury.

Authors:  Zemin Cao; Fabrice Bonnet; Riccardo Candido; Stefan P Nesteroff; Wendy C Burns; Hiroshi Kawachi; Fujio Shimizu; Robert M Carey; Marc De Gasparo; Mark E Cooper
Journal:  J Am Soc Nephrol       Date:  2002-07       Impact factor: 10.121

10.  Overexpression of angiotensin type 2 receptor ameliorates glomerular injury in a mouse remnant kidney model.

Authors:  Naoko Hashimoto; Yohei Maeshima; Minoru Satoh; Masahiro Odawara; Hitoshi Sugiyama; Naoki Kashihara; Hiroaki Matsubara; Yasushi Yamasaki; Hirofumi Makino
Journal:  Am J Physiol Renal Physiol       Date:  2003-10-28
View more
  5 in total

1.  Polyploidy and Mitotic Cell Death Are Two Distinct HIV-1 Vpr-Driven Outcomes in Renal Tubule Epithelial Cells.

Authors:  Emily H Payne; Dhivya Ramalingam; Donald T Fox; Mary E Klotman
Journal:  J Virol       Date:  2018-01-02       Impact factor: 5.103

Review 2.  Modulation of mTORC1 Signaling Pathway by HIV-1.

Authors:  Burkitkan Akbay; Anna Shmakova; Yegor Vassetzky; Svetlana Dokudovskaya
Journal:  Cells       Date:  2020-04-28       Impact factor: 6.600

3.  Aliskiren attenuates cardiac dysfunction by modulation of the mTOR and apoptosis pathways.

Authors:  Zhengbo Zhao; Han Liu; Dongmei Guo
Journal:  Braz J Med Biol Res       Date:  2020-01-24       Impact factor: 2.590

Review 4.  Hypertension and Metabolic Syndrome in Persons with HIV.

Authors:  Sepiso K Masenga; Fernando Elijovich; John R Koethe; Benson M Hamooya; Douglas C Heimburger; Sody M Munsaka; Cheryl L Laffer; Annet Kirabo
Journal:  Curr Hypertens Rep       Date:  2020-09-03       Impact factor: 5.369

5.  HIV-1 Vpr suppresses expression of the thiazide-sensitive sodium chloride co-transporter in the distal convoluted tubule.

Authors:  Shashi Shrivastav; Hewang Lee; Koji Okamoto; Huiyan Lu; Teruhiko Yoshida; Khun Zaw Latt; Hidefumi Wakashin; James L T Dalgleish; Erik H Koritzinsky; Peng Xu; Laureano D Asico; Joon-Yong Chung; Stephen Hewitt; John J Gildea; Robin A Felder; Pedro A Jose; Avi Z Rosenberg; Mark A Knepper; Tomoshige Kino; Jeffrey B Kopp
Journal:  PLoS One       Date:  2022-09-21       Impact factor: 3.752

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.